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The alpha--adrenoceptor located on noradrenergic neu-
rons regulates the release of norepinephrine by negative
feedback. This receptor is also located on human blood
platelets, and the number of these receptors is correlated
with the plasma norepinephrine content. The purpose
of this study was to determine the status of platelet alphas-
adrenoceptors in patients with symptomatic and asymp-
tomatic coronary artery disease. It was hypothesized
that patients with symptomatic coronary disease might
have a decrease in alpha--adrenocepter number that might
be related to increased neuronal norepinephrine release.
Specific, high-affinity binding of the alpha--agonist, "H-
clonidine, and the alphas-antagonist, 3H-yohimbine, to
isolated platelet membranes was used to determine the
maximal number of binding sites (in fmol/mg protein ±
standard error of the mean) and the dissociation constant
(in oM) of the alpha--receptors.
In normal subjects, the number of binding sites for
3H-clonidine was 32 ± 2 and the dissociation constant
was 5.5 ± 0.6 (n = 26); the maximal number of binding
sites for 3H-yohimbine was 165 ± 12and the dissociation
constant was 4.0 ± 0.5 (n = 16). In patients with symp-
tomatic coronary artery disease, there was a 38% de-
crease in "H-clonidine binding (number of binding sites
Alpha-adrenergic stimulation has been shown to modulate
coronary artery tone in conscious dogs (1,2). in canine myo-
cardium (3) and in human subjects (4,5). The importance
of the alpha-adrenergic system in this role has been shown
after both nerve stimulation (6) and the infusion of norep-
inephrine (7). Postsynaptic alpha--adrenoceptors play an irn-
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= 20 ± 3; dissociation constant = 6.6 ± 1.2; n = 9;
P < 0.05) and a 44% decrease in 3H-yohimbine binding
(number of binding sites = 93 ± 8; dissociation constant
= 4.5 ± 0.3; n = 18; p < 0.005). In patients with
asymptomatic coronary artery disease, there were no
significant changes from the normal population in bind-
ing with either ligand eH-clonidine: number of binding
sites = 30 ± 2; dissociation constant = 6.9 ± 1.9; n
= 6 and 3H-yohimbine: number of binding sites = 137
± 11; dissociation constant = 5.1 ± 0.6; n = 10). Five
patients were studied during a symptomatic phase of
their disease and then restudied during a quiescent pe-
riod. In this group, the number of alpha.-adrenoceptors
increased markedly as shown in 3H-clonidine from 16
± 3 to 29 ± 3 (44%, P < 0.005) and in 3H-yohimbine
from 69 ± 22 to 127 ± 17 (46%, P < 0.05).
The affinity constants and plasma norepinephrine
concentrations did not differ among the three groups.
If similar changes in receptor number occur on nerve
terminals, this may represent a primary abnormality
that permits enhanced release of norepinephrine or a
secondary down regulation of receptor number in re-
sponse to increased synaptic levels of norepinephrine.
portant role in coronary vasoconstriction elicited by both
sympathetic nerve stimulation and infused norepinephrine
(8) and in regulating the tone of both large and small coro-
nary arteries (9). Coronary artery vasoconstriction may be
induced by adrenergic stimulation, even in the presence of
experimentally produced coronary artery stenosis (10) or
adenosine-induced maximal coronary artery dilation (II).
The presynaptic alphayadrenoceptor is an autoreceptor
that exhibits a negative feedback inhibition on the neuronal
release of norepinephrine (12,13). This has been suggested
to be important in modulating coronary artery responses to
sympathetic nerve stimulation (14). In isolated rat heart, a
strong correlation has been found between the sensitivity of
alphavpresynaptic receptor sites and the amount of norep-
inephrine released at the nerveterminal (15.16).Thesechanges
are accompanied by changes in alphayadrenoceptor number
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on rat brain neural membranes (17) and on human platelets
(18).
It was our hypothesi s in the present study that patients
with symptomatic coronary artery disease might have fewer
of these presynaptic inhibitory receptor s. This could lead to
increases in norepinephrine release at the nerve terminal
and , in tum , to increased vascular tone or spasm. The human
blood platelet has been suggested as a model for the adren-
ergic neuron (19). Its membrane contains the same alpha--
adrenoceptor found on presynaptic nerve terminals (20).
This study was designed to characterize the platelet alpha--
adrenoceptor using radioligand binding techniques in pa-
tients with both symptomatic and asymptomatic coronary
artery disease and to relate any changes in receptor number
or affinity to levels of circulating norepinephrine and degree
of symptoms.
Methods
Study patients. Blood was obtained by venipuncture
from 26 healthy male and female volunteers (mean age ±
standard error of the mean 40 ± 3 years). These control
subjects were compared with 28 patients with coronary ar-
tery disease as documented by exerci se testing and cardiac
catheterization . The patients were divided into two groups
based on the presence or absence of anginal episodes during
the previous 2 weeks . The 18 symptomatic patients in Group
I had a mean age of 56 ± 3 years and the 10 asymptomatic
patients in Group II had a mean age of 58 ± 4 years . The
groups were evenly matched in terms of the anatomic extent
of disease, with Group I having 15 patients with multivessel
and 3 with single vessel disease and Group II having 8
patients with multivessel and 2 with single vessel involve-
ment. Coronary vessel involvement was defined as diameter
narrowing greater than 50%. There was no difference in the
two groups between percent luminal stenoses. No patient
in either group had a history of congestive heart failure or
had a moderately or markedly reduced ejection fraction as
determined by cineangiography.
Previous work (20, 21) has shown the lack of age or sex
dependency of either the total number or the affinity of the
platelet alpha j-adrenoceptor. There was no difference in the
number of binding sites or the affinity in control subjects
or patient s over or under the age of 60 . For at least 1 month
before the study, all patients were free of drugs that might
modify the alpha j-adrenoceptor, such as c1onidine, alpha
methyldopa, tricyclic antidepressants or adrenergic ino-
tropic agents . Two patients in Group I (Cases 38 and 42)
and two patients in Group II (Cases 49 and 51) were on
stable doses of propranolol. No patient in these groups was
being treated with a calcium channel antagonist.
Of the five patients who were studied while symptomatic
and then again when asymptomatic , two (Cases 49 and 50)
underwent coronary artery bypass grafting before repeat
testing . One patient (Case 47) was treated with nifedipine ,
a calcium channel antagoni st, during this period. No patient
in this group was receiving beta-adrenergic antagonists.
Informed consent was obtained from all patients. Ap-
proval of this study was obtained from the Institutional
Review Board of the University of Michigan in May 1980.
Isolation of platelet membranes and radioligand bind-
ing assay. Platelet membranes were obtained using the
method of Garcia-Sevilla et al. (20). In brief, 50 ml of blood
was collected in acid-citrate dextrose (ACD) (8: I, v/v). The
blood was centrifuged at 160 x g for 10 minutes (25°C),
and the platelet-rich plasma was titrated to pH 6.5 with the
ACD solution. This was then recentrifuged at 5,100 x g
for 15 minutes (25°C) to obtain a platelet pellet. The pellet
was washed twice with 5 ml of Tyrode's buffer [mM: so-
dium chloride (NaCI), 137; potas sium chloride (KCI), 2.7;
sodium phosphate, monobasic (NaH2P04) , 0.36; magne-
sium chloride (MgCI2) , 0.01; sodium bicarbonate (Na-
HC03), 12.0; dextrose, 0.56; pH, 8.0] and recentrifuged
for 15 minutes at 5,100 x g. The pellet was lysed by
homogenization in 2 ml of ice cold hypertonic buffer (Tris-
EDTA, 5 mM, pH 7.5) . The platelet membranes were ob-
tained by centrifugation at 39,000 x g for 10 minutes and
then resuspended in the Tris incubation buffer (mM : Tris-
HCI, 50; MgCh, 10; pH, 7.5 ) used in the binding assay.
Total radioligand binding, using 3H-c1onidine, an alpha .-
adrenoceptor agonist, and 3H-yohimbine, an alpha--adreno-
ceptor antagonist (New England Nuclear), was measured in
I ml aliquots of the fresh platelet membranes (0.282 ±
0.22 mg protein), which were incubated in duplicate at 25°C
for 20 minutes with the radioligand. Nonspecific binding
was determined by adding unlabeled cIonidine or yohim-
bine, 10- 5 M, in addition to the respective tritiated ligand,
to a second pair of incubates. Specific binding was defined
as the difference between total and nonspecific binding .
Incubations were terminated by adding 5 ml of the Tris
incubation buffer to the sample . The membrane-bound tri-
tiated ligand was recovered by rapid filtration of the diluted
sample under vacuum through Whatman GF/C glass-fiber
filters. The filters were washed twice with 10 ml of Tris
incubation buffer, air-dried and counted for radioactivit y as
described by Smith et al. (22). Proteins were determined
by the method of Lowry et al. (23).
Scatchard analysi s of the saturation isotherms was used
to determine the maximal number of binding sites (x-inter-
cept of a plot of specifically bound ligand versus bound/free
ligand) and the dissociation constant (negative reciprocal of
the slope of the regression line) (24) .
Catecholamine determinations. Catecholamine deter-
minations were performed using the radioenzymatic assay
of Passon and Peuler (25) . The rat liver catechol-O-meth-
yltransferase was isolated according to the method of Ax-
elrod and Tomchik (26). All samples were obtained by
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relatively atraumatic venipuncture with the patient recum-
bent for at least 30 minutes, a method that does not alter
the catecholamine concentration (27). The blood was col-
lected in ACD, and the serum was immediately frozen at
-70°C,
Statistical analysis. Statistical analysis was performed
using Student's t test. Correlation coefficients (r) were ob-
tained by linear regression analysis using the method of
least squares. Significance was defined as a probability (p)
value less than 0.05.
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3H-yohimbine (n = 16; number of binding sites = 165 ±
12; dissociation constant = 4.0 ± 0.5).
Binding data in patients with symptomatic and asymp-
tomatic coronary disease. Patients with symptomatic cor-
onary artery disease (Group I, n = 18, Table 2A) had
binding data that showed highly significant decreases in
maximal number of binding sites, as defined by both 3H_
clonidine binding (20 ± 6.6, 38%; P < 0.05; Fig. 1) and
by 3H-yohimbine binding (93 ± 8, 44%; P < 0.005; Fig.
2). The number of binding sites in patients with asympto-
matic coronary artery disease (Group II, Table 2B) did not
differ significantly from that in the control subjects CH-
clonidine binding: 30 ± 2, n = 6 and 3H-yohimbine bind-
ing: 137 ± 11, n = 10).
The dissociation constant of the ligands for the binding
sites did not differ significantly between the control group
and Groups I and II. For 3H-clonidine, the dissociation
constant was 6.6 ± 1.2 in Group I and 6.9 ± 1.9 in Group
4 8
IH-YOHIMBINE (oM)
Figure 2. Specific binding of 3H-yohimbine to platelet membranes
from normal subjects (closed circles) and from patients with symp-
tomatic coronary artery disease (closed triangles) as a function of
increasing concentrations (0.25 to 16 nM) of the ligand. Ordinate:
3H-yohimbine specifically bound (fmol/mg protein). Abscissa:
concentration of 3H-yohimbine (nM). Inset: Scatchard plot show-
mg the difference in the number of high affinity binding sites
(normal subjects: maximal number of binding sites = 165 ± 12;
dissociation constant = 4.0 ± 0.5 versus patients with sympto-
mane disease: maximal number of binding sites = 93 ± 8; dis-
sociation constant = 4.5 ± 0.3; p < 0.005). Each point represents
the mean ± standard error of the mean. B = specifically bound
ligand; B/F = bound/free ligand.
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Results
Binding data in normal control subjects. The specific
binding of both 3H-clonidine and 3H-yohimbine to platelet
membranes from both normal subjects and patients with
coronary artery disease was both saturable and of high af-
finity (Fig. 1 and 2). The lack of correlation between age
and sex and the number of binding sites or the affinity of
the radioligand for the receptor site was confirmed as seen
in previous studies (20,21). The individual data for the
control population are shown in Table lA for 3H-clonidine
(n = 26; maximal number of binding sites = 32 ± 2;
dissociation constant = 5.5 ± 0.6) and in Table IB for
Figure 1. Specific binding of 3H-clonidine to platelet membranes
from normal subjects (closed circles) and from patients with symp-
tomatic coronary artery disease (closed triangles) as a function of
increasing concentrations (I to 64 nM) of the ligand. Ordinate:
3H-clonidine specifically bound (fmol/mg protein). Abscissa: con-
centration of 3H-clonidine (nM). Inset: Scatchard plot showing
the difference in the number of high-affinity binding sites (normal
subjects: maximal number of binding sites = 32 ± 2; dissociation
constant = 5.5 ± 0.6 versus patients with symptomatic disease:
maximal number of binding sites = 20 ± 3.3; dissociation con-
stant = 3.3; p < 0.05). Each point represents the mean ± standard
error of the mean. B = specifically bound ligand; B/F = bound/
free ligand.
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II. For 3H-yohimbine, this constant was 4.5 ± 0.3 in Group
I and 5.1 ± 0.6 in Group II.
Table 1. 3H-Clonidine and 3H-Yohimbine Binding to Platelet
Membranes of Normal Subjects
High Affinity Binding
Age (yr) Bm3x (fmollmg KD
Case &Sex protein) (nM)
A. 3H-Clonidine Binding
I 34M 33 48
2 19M 29 4.8
3 23M 32 6.9
4 43M 28 8.7
5 27M 40 5.2
6 44F 51 4.8
7 36F 36 4 I
8 23M 48 57
9 26F 29 5.1
10 22M 20 6.9
II 28M 48 5.8
12 31M 52 5.8
13 20F 39 4.7
14 27F 29 4.6
15 30F 18 I 7
16 31M 21 03
17 57M 22 1.4
18 67M 32 4.5
19 55F 44 9.9
20 69F 44 8.0
21 70F 32 2.8
22 48M 28 132
23 56M 35 12.9
24 39F 23 54
25 45M 19 I 8
26 62M 31 68
Mean 40 33 5.5
± SEM 3 2 0.6
B. 3H-Yohimbine Binding
I 34M 245 3.1
6 44F 214 3.6
II 28M 166 2.5
12 31M 160 2.5
13 20F 186 30
14 27F 133 32
22 48M 57 2.9
23 56M 174 5.0
24 39F 124 7.8
26 62M 138 43
27 49M 123 4.3
28 60F 146 92
29 20M 168 2.5
30 28M 166 3.1
31 40F 208 3.4
32 24F 238 2.9
Mean 37 165 4.0
± SEM 4 12 05
Bm3x = maximal number of binding sites; KD = dissociation constant:
SEM = standard error of the mean.
Binding data in patients during and after a period of
symptomatic disease. In the five patients studied both dur-
ing and after a period of sympotomatic disease, the number
of binding sites changed significantly in the same manner
as in the patient group comparisons (Fig. 3 and 4). When
the patients were symptomatic, the maximal number of bind-
ing sites for specific binding of 3H-clonidine was 16 ± 3;
whereas it increased to 29 ± 3 on follow-up testing (p <
0.005). For specific binding of 3H-yohimbine, the initial
number of binding sites was 93 ± 8 and was 127 ± 17 (p
< 0.05) on repeat testing. Again, the affinity constants were
unchanged eH-clonidine: 7.3 ± 2.1 to 5.9 ± 2.0 and 3H_
yohimbine: 4.4 ± 0.6 to 5.9 ± 0.9).
Catecholamine values. Plasma norepinephrine, epi-
nephrine and dopamine were measured in all control subjects
and patients. In normal subjects, the norepinephrine con-
centration was 385.1 ± 63.9 pg/ml (range 54 to 908). There
was no significant difference from control values in nor-
epinephrine content in Group I (symptomatic) patients (483.5
± 82.1 pg/ml; range 199 to 1,495) or in Group II (asymp-
tomatic) patients (379.8 ± 85.6 pg/rnl; range 58 to 897).
Although there was a trend toward an increase in epinephrine
concentration in patients in Group I (104.0 ± 22.5 pg/rnl;
range 0 to 274) and Group II (93.6 ± 16.8 pg/ml; range
33 to 189), these values did not differ significantly from
those of the normal group (53.6 ± 12.7 pg/ml; range 8 to
163). There was no significant difference in dopamine con-
tent among the three groups (normal: 13.9 ± 7.8 pg/ml,
range 0 to 100; Group I: 34.8 ± 10.3 pg/ml, range 0 to
143; Group II: 25.8 ± 7.8 pg/ml, range 0 to 81).
Discussion
Alpha-adrenergic activity in coronary arteries. The
importance of the alpha-adrenergic system in determining
coronary vascular tone has been suggested by several in-
vestigators (1-11). Even in the presence of local metabolic
vasodilation, sympathetic vasoconstriction was capable of
limiting oxygen delivery to the myocardium (10, II). The
increase in coronary vascular resistance after cold pressor
testing has been shown to be inhibited by alpha-adrenergic
blockade with phentolamine (5). The increase in resistance
was greater in patients with coronary artery disease than in
patients with normal coronary arteries. This suggested that
changes in the alpha-adrenergic system's response to stimuli
may be involved in determining vascular tone, particularly
in atherosclerotic vessels.
Bassenge et al. (8) examined the presence and role of
vascular alphayadrenoceptors in the coronary bed of dogs.
Coronary constriction was elicited by both infused norepi-
nephrine and sympathetic nerve stimulation that was inhib-
ited by alpha--blockade with rauwolscine. The increased
release of norepinephrine during nerve stimulation after alpha--
lACC Vol 2. No 4
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Table 2. JH_Yohimbine and ' H-C1onidine Binding to Platelet Membranes of Patients With Symptomatic and Asymptomatic Coronary
Artery Disease
' H-Yohimbine Binding JH-Clonidine Binding
BOl •n Bm •n :
Age (yr) (fmol/mg KD (frnol/mg Ko
Case &Sex protein ) (nM) protein) (nM)
A Patients With Symptomatic Coronary Artery Disease
33 57M 100 4 4 5
34 36M 138 4 4 9
35 57M 104 6 2.6
36 62M 92 3 2.4
37 55M 99 7 5. \
38 60M 368 3.8 422 3 5
39 47M 116 0 4.8
40 60M 1250 3.8
4 1 54M 117 8 3.0 18 8 5 4
42 72F 850 5.3 12 7 76
43 56M 11 0 I 4 1 265 65
44 47M 114 2 7.3
45 62F 96 7 3 3
46 60F 120.7 43 17. I 3.0
47 40M II 0 2.6 10.0 20
48 42M 3 1 0 5.0 10 .9 88
49 65F 113 4 4 1 22.7 13.4
50 68F 66 7 6.0 20.9 9.4
Mean 56 93 3 4 5 20 2 6 .6
± SEM 3 83 03 3.3 1.2
B. Patients With Asymptomatic Coronary Artery Disease
46 60F \85.4 4 4 258 2.9
47* 40M 92 1 5.3 22.5 1.6
48 42M 9 1 3 3.9 370 74
49 65F 1372 9.0 295 45
50 68F 129 4 6 6 32 I 13. 1
5 \ 49M 15 1 9 43
52 17M 192 6 2 5
53 59M 150 0 37
54 59M 100 4 4 0
55 57M 139 6 7.6
Mean 58 137 0 5 1 29.6 6.9
:!: SEM 4 II z 06 2. 1 1.9
*Patlent treated with rnfedipmc Abbreviations as In Tab le I
adrenoceptor blockade suggested a physiologically signifi-
cant role for the presynaptic alpha, site in the whole animal.
Johannsen et al. (14) have shown that the infusion of clon-
idine, an alpha--agonist, into dogs inhibited coronary va-
soconstriction due to sympathetic nerve stimulation but not
to infused norepinephrine. This response to clonidine pre-
sumably resulted from the stimulation of the presynaptic
alpha--adrenoceptor and inhibition of norepinephrine re-
lease. These observations are consistent with the importance
of alpha-adrenergic control of coronary vascular tone and
with the ability of the presynaptic alpha, site to modulate
the release of norepinephrine from the sympathetic nervous
system.
Platelet alphaj-adrenoreceptors. The alpha-adreno-
ceptor on the human platelet has been well characterized as
being of the alpha, subtype (20). Stimulation of presynaptic
alpha--receptors inhibits the neuronal release of norepi-
nephrine (12,13). Thus, a decrease in number of this in-
hibitory site would be expected to permit increased nor-
epinephrine release with nerve stimulation. Changes in the
number of platelet alpha-receptors have been shown to
correlate with changes in similar neuronal receptors in the
rat brain after various therapies such as antidepressant drug
treatment (17,18,20) and electroconvulsive shock therapy
(28). Similar interventions caused decreases in receptor sen-
sitivity. which resulted in increased norepinephrine release
after nerve stimulation as measured by the tensiondeveloped
by rat atrial strips during field stimulation (15,16). There is
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Figure 3. Comparisonofspecific binding of3H-clonidine toplate-
let membranes as determined by Scatchard analysis for a repre-
sentative patient (Case 46) when symptomatic (closed triangles)
andagain when asymptomatic (closed circles). Abscissa: maximal
number of binding sites in fmol/mg protein . B = specifically
bound ligand; B/F = bound/free ligand.
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Figure 4. Comparison of specific binding of 3H-yohimbine to
platelet membranes as determined by Scatchard analysis for a
representative patient (Case 46) when symptomatic (closed tri-
angles) andagain when asymptomatic (closed circles). Abscissa:
maximal number of binding sites in fmol/mg protein. B = spe-
cifically bound ligand; B/F = bound/free ligand.
in the amount of norepinephrine released, perhaps even
within the normal range, may be important in affecting
vascular tone if atherosclerotic vessels are supersensitive to
catecholamines, as has been suggested (34).
Clinical implications. Abnormalities of the adrenergic
nervous system have been found in the variant angina syn-
drome (35-37) . It has been suggested that vasospasm may
underlie much of myocardial ischemia (38) . Several studies
(38) have shown no increase in myocardial oxygen demand
before an episode at rest or. in some cases, during exercise-
induced angina. Circumstantial evidence for the importance
of spasm in patients with unstable angina is found in pro-
pranolol's reported lack of efficacy in decreasing the number
of ischemic episodes at rest (39) or in actually causing an
increase in the duration of such episodes (40).
Changes in vasomotor tone may be important in causing
stable angina. In this study, the change in the number of
platelet alpha--adrenoceptors reflected changes in the symp-
tomatic activity of the coronary artery disease, with a de-
crease in receptor number correlating with increased symp-
toms. If the decrease in alpha-adrenoceptor number found
during periods of symptomatic coronary artery disease is
primary, this could permit an increased release of neuronal
norepinephrine during nerve stimulation. This increase could
cause coronary artery vasoconstriction, even at times of
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an inverse relation between the number of alpha--adreno-
ceptors on platelets and circulating norepinephrine levels in
patients with chronic congestive heart failure (21).
It is not absolutely certain from the present study whether
the decrease in receptor number is a primary change related
to the underlying disease or a secondary change related to
transient changes in the concentrations of circulating cate-
cholamines. Increased plasma concentrations of circulating
norepinephrine, epinephrine or dopamine were not found in
either of our patient groups with angina. This is consistent
with work done by Schwartz et al. (29), who found no
change in the peripheral catecholamine concentration of pa-
tients after pacing to angina. Robertson et al. (30) also found
no abnormalities in plasma catecholamines or their urinary
metabolites in patients with variant angina. Any increase in
plasma norepinephrine may be very transient. The half-time
of 3H-norepinephrine has been shown to be 5 minutes in
mice and 2 minutes in cats (31,32) . It is possible that changes
in platelet alphaj-adrenocepror number reflect transient
changes in the norepinephrine concentration in a manner
similar to that in which glycosalated hemoglobin reflects
transient changes in glucose concentration (33). Small changes
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maximal vasodilation due to local metabolic factors . If the
decrease is secondary to increa sed concentrations of nor-
epinephrine, then it might be an important marker of in-
creased adrenergic activity that may be related to episodes
of angina.
We gratefully acknowledge the technical assistance provided by Joann
Geer, Sarah Jane Moss and Curns Wertz .
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